Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.

California Regional Primate Research Center, School of Medicine, University of California, Davis 95616, USA.
Journal of Virology (Impact Factor: 4.65). 08/2000; 74(13):6087-95. DOI: 10.1128/JVI.74.13.6087-6095.2000
Source: PubMed

ABSTRACT Despite recent insights into mucosal human immunodeficiency virus (HIV) transmission, the route used by primate lentiviruses to traverse the stratified squamous epithelium of mucosal surfaces remains undefined. To determine if dendritic cells (DC) are used by primate lentiviruses to traverse the epithelial barrier of the genital tract, rhesus macaques were intravaginally exposed to cell-free simian immunodeficiency virus SIVmac251. We examined formalin-fixed tissues and HLA-DR(+)-enriched cell suspensions to identify the cells containing SIV RNA in the genital tract and draining lymph nodes within the first 24 h of infection. Using SIV-specific fluorescent in situ hybridization combined with immunofluorescent antibody labeling of lineage-specific cell markers, numerous SIV RNA(+) DC were documented in cell suspensions from the vaginal epithelium 18 h after vaginal inoculation. In addition, we determined the minimum time that the SIV inoculum must remain in contact with the genital mucosa for the virus to move from the vaginal lumen into the mucosa. We now show that SIV enters the vaginal mucosa within 60 min of intravaginal exposure, infecting primarily intraepithelial DC and that SIV-infected cells are located in draining lymph nodes within 18 h of intravaginal SIV exposure. The speed with which primate lentiviruses penetrate mucosal surfaces, infect DC, and disseminate to draining lymph nodes poses a serious challenge to HIV vaccine development.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have demonstrated that substantial levels of HIV-1 replication occur in vivo in what appear to be 'resting' CD4(+) T lymphocytes. This contrasts with numerous studies in vitro, in which resting T cells are not permissive for productive infection as a result of a number of barriers to infection, particularly during the early stages of the viral life cycle. The barriers in vitro are likely to be the result of limiting levels of cellular cofactors that mediate viral replication, and these cofactors are apparently present at adequate levels in resting cells in vivo. Although a number of HIV-1 cofactors are now known, it is important to identify additional cofactors and to characterize the expression pattern and mechanisms that regulate cofactor function in infected CD4(+) T lymphocytes in vivo. It may ultimately become possible to manipulate the expression levels of essential HIV-1 cofactors in vivo and thereby recapitulate for therapeutic benefit the barriers to infection that exist in resting T cells in vitro.
    Future Virology 05/2006; 1(3):337-347. DOI:10.2217/17460794.1.3.337 · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF) or TDF-emtricitabine (FTC) has been shown to be effective against sexual and injection-drug related HIV acquisition in four out of six large clinical trials. This article reviews the pharmacology of TDF and FTC as it relates both to PrEP efficacy and the emergence of viral resistance, summarizes the six trials and the inherent challenges to PrEP they highlighted, and proposes some future areas for further exploration.
    Future Virology 12/2013; 8(12):1207-1218. DOI:10.2217/fvl.13.111 · 1.00 Impact Factor
  • The Journal of Infectious Diseases 10/2013; 208(suppl 2):S131-S136. DOI:10.1093/infdis/jit318 · 5.78 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014